ArticleScientific reports2020
Extent of resection and molecular pathologic subtype are potent prognostic factors of adult WHO grade II glioma.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Impact of awake mapping on extent of resection and neurological outcomes of Low-grade gliomas: a systematic review and Meta-analysis.Neurosurgical review · 2025Pooled it
- Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of surgery in the management of patients with diffuse low grade glioma: update.Journal of neuro-oncology · 2025Pooled it
- Congress of Neurological Surgeons systematic review and evidence‑based guidelines on the management of recurrent diffuse low-grade glioma: update.Journal of neuro-oncology · 2025Guideline
- Gross Total Resection and Recurrence-Free Survival in Diffuse Gliomas: A Single-Center Cohort Study from Eastern Europe.Clinics and practice · 2026Article
- The Dual Impact of Glioma Resection on Survival and Health-Related Quality of Life: Resect More, Live Better.Brain tumor research and treatment · 2026Article
- Comprehensive analysis of clinical, pathological, and molecular risk factors affecting the prognosis of patients with glioma.Medicine · 2025Observational
- Treatment of IDH-mutant glioma in the INDIGO era.NPJ precision oncology · 2024Review
- Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas.Neuro-oncology · 2024Article
- Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification.European radiology · 2024Article
- Decision system for extent of resection in WHO grade 3 gliomas: a Chinese Glioma Genome Atlas database analysis.Journal of neuro-oncology · 2023Article
- Supramaximal Resection for Glioblastoma: Redefining the Extent of Resection Criteria and Its Impact on Survival.Brain tumor research and treatment · 2023Review
- Intraoperative detection of IDH-mutant glioma using fluorescence lifetime imaging.Journal of biophotonics · 2023Article
- Same but different. Incidental and symptomatic lower grade gliomas show differences in molecular features and survival.Journal of neuro-oncology · 2023Article
- Association of dynamic susceptibility contrast- and dynamic contrast-enhanced magnetic resonance imaging parameters with molecular marker status in lower-grade gliomas: A retrospective study.The neuroradiology journal · 2023Article
- Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics.Neuro-oncology · 2023Article
- LITTing up Gliomas-Is the Future Bright?World neurosurgery: X · 2023Article
- Benign Glioma.Advances in experimental medicine and biology · 2023Article
- High-throughput analysis of tissue microarrays using automated desorption electrospray ionization mass spectrometry.Scientific reports · 2022Article
- Preoperative [11C]methionine PET to personalize treatment decisions in patients with lower-grade gliomas.Neuro-oncology · 2022Article
- IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroups.Neuro-oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated prognostic factors of adult low-grade glioma (LGG) according to the new 2016 WHO classification. Records of 153 patients diagnosed with WHO grade II LGG between 2003 and 2015 were retrospectively reviewed. Based on the 2016 WHO classification, 80 patients (52.3%) had diffuse astrocytoma, IDH-mutant; 45 (29.4%) had oligodendroglioma, IDH-mutant and 1p/19q-codeleted (ODG); and 28 (18.3%) had diffuse astrocytoma, IDH-wildtype. Gross total resection (GTR) was performed in 71 patients (46.4%), subtotal resection in 31 (20.3%), partial resection in 43 (28.1%), and biopsy in 8 (5.2%). One hundred two patients (66.7%) received postoperative radiotherapy. The 5- and 10-year progression-free survival (PFS) rates were 72.7% and 51.5%, respectively, and the 5- and 10-year overall survival (OS) rates were 82.5% and 63.5%, respectively. GTR and IDH-mutant and/or 1p/19q codeletion were favorable prognostic factors for PFS and OS. Patients with IDH-wildtype had significantly decreased OS. Among patients with ODG who underwent GTR, no recurrence was observed after radiotherapy. Patients who underwent non-GTR frequently experienced recurrence after radiotherapy (IDH-mutant: 47.6%, IDH-wildtype: 57.9%). In conclusion, molecular classification of LGG was of prognostic relevance, with IDH-wildtype patients having a particularly poor outcome, regardless of the treatment. Favorable results were observed in patients who underwent GTR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.